Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy: Research paper

British Journal of Haematology

Volumn 150, Issue 1, 2010, Pages 39-45

  Dickinson, Michael ^a   Hoyt, Rosemary ^b   Roberts, Andrew W ^b,c   Grigg, Andrew ^b,c   Seymour, John F ^a,c   Prince, H Miles ^a,c   Szer, Jeff ^b,c   Ritchie, David ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Autologous transplantation; Diffuse Large B Cell Lymphoma; Positron emission tomography

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUORODEOXYGLUCOSE; GEMCITABINE; IFOSFAMIDE; NAVELBINE; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG SUBSTITUTION; FEMALE; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPIDEMIOLOGIC METHODS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RECURRENCE; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953527083     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08162.x     Document Type: Article

References (35)

1. Becherer, A., Mitterbauer, M., Jaeger, U., Kalhs, P., Greinix, H.T., Karanikas, G., Potzi, C., Raderer, M., Dudczak, R. Kletter, K. (2002) Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia, 16, 260 267.
2. Blay, J., Gomez, F., Sebban, C., Bachelot, T., Biron, P., Guglielmi, C., Hagenbeek, A., Somers, R., Chauvin, F. Philip, T. (1998) The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood, 92, 3562 3568.
3. Bondly, C.C., Johnston, P.B., Lowe, V.J., Ansell, S.M., Inwards, D.J., Porrata, L.F. Micallef, I.N. (2006) Positive positron emission tomography (PET) pre-autologous stem cell transplant (ASCT) in non-Hodgkin lymphoma (NHL) does not preclude successful outcome. Biology of Blood and Marrow Transplantation, 12, 18 19.
4. Caballero, M.D., Rubio, V., Rifon, J., Heras, I., García-Sanz, R., Vázquez, L., Vidriales, B., del Cañizo, M.C., Corral, M., Gonzalez, M., León, A., Jean-Paul, E., Rocha, E., Moraleda, J.M. San Miguel, J.F. (1997) BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplantation, 20, 451 458.
5. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579 586.
6. Dupuis, J., Gaulard, P., Hemery, F., Itti, E., Gisselbrecht, C., Rahmouni, A., Copie-Bergman, C., Briere, J., El Gnaoui, T., Gaillard, I., Meignan, M. Haioun, C. (2007) Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. Haematologica, 92, 778 783.
7. Dupuis, J., Itti, E., Rahmouni, A., Hemery, F., Gisselbrecht, C., Lin, C., Copie-Bergman, C., Belhadj, K., El Gnaoui, T., Gaillard, I., Kuhnowski, F., Meignan, M. Haioun, C. (2008) Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Annals of Oncology, 20, 503 507.
8. Filmont, J.E., Czernin, J., Yap, C., Silverman, D.H., Quon, A., Phelps, M.E. Emmanouilides, C. (2003) Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest, 124, 608 613.
9. Filmont, J.E., Gisselbrecht, C., Cuenca, X., Deville, L., Ertault, M., Brice, P., De Kerviler, E., Briere, J., Larghero, J., Moretti, J.L. Mounier, N. (2007) The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer, 110, 1361 1369.
10. Guglielmi, C., Gomez, F., Philip, T., Hagenbeek, A., Martelli, M., Sebban, C., Milpied, N., Bron, D., Cahn, J.Y., Somers, R., Sonneveld, P., Gisselbrecht, C., Van Der Lelie, H. Chauvin, F. (1998) Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. Journal of Clinical Oncology, 16, 3264 3269.
11. Haioun, C., Itti, E., Rahmouni, A., Brice, P., Rain, J.D., Belhadj, K., Gaulard, P., Garderet, L., Lepage, E., Reyes, F. Meignan, M. (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood, 106, 1376 1381.
12. Hamlin, P.A., Zelenetz, A.D., Kewalramani, T., Qin, J., Satagopan, J.M., Verbel, D., Noy, A., Portlock, C.S., Straus, D.J., Yahalom, J., Nimer, S.D. Moskowitz, C.H. (2003) Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 102, 1989 1996.
13. Horning, S.J., Chao, N.J., Negrin, R.S., Hoppe, R.T., Long, G.D., Hu, W.W., Wong, R.M., Brown, B.W. Blume, K.G. (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood, 89, 801 813.
14. Horning, S.J., Juweid, M.E., Schoder, H., Wiseman, G., McMillan, A., Swinnen, L.J., Advani, R., Gascoyne, R. Quon, A. (2009) Interim positron emission tomography (PET) scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood, 115, 775 777.
15. Jerusalem, G., Beguin, Y., Fassotte, M.F., Najjar, F., Paulus, P., Rigo, P. Fillet, G. (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica, 85, 613 618.
16. Johnston, P., Wiseman, G. Micallef, I. (2008) Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma. Bone Marrow Transplantation, 41, 919 925.
17. Juweid, M., Stroobants, S., Hoekstra, O., Mottaghy, F., Dietlein, M., Guermazi, A., Wiseman, G., Kostakoglu, L., Scheidhauer, K., Buck, A., Naumann, R., Spaepen, K., Hicks, R., Weber, W., Reske, S., Schwaiger, M., Schwartz, L., Zijlstra, J., Siegel, B. Cheson, B. (2007) Use of Positron Emission Tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. Journal of Clinical Oncology, 25, 571 578.
18. Kewalramani, T., Zelenetz, A.D., Hedrick, E.E., Donnelly, G.B., Hunte, S., Priovolos, A.C., Qin, J., Lyons, N.C., Yahalom, J., Nimer, S.D. Moskowitz, C.H. (2000) High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood, 96, 2399 2404.
19. Kewalramani, T., Zelenetz, A.D., Nimer, S.D., Portlock, C., Straus, D., Noy, A., O'Connor, O., Filippa, D.A., Teruya-Feldstein, J., Gencarelli, A., Qin, J., Waxman, A., Yahalom, J. Moskowitz, C.H. (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 103, 3684 3688.
20. Kostakoglu, L., Goldsmith, S.J., Leonard, J.P., Christos, P., Furman, R.R., Atasever, T., Chandramouly, A., Verma, S., Kothari, P. Coleman, M. (2006) FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer, 107, 2678 2687.
21. Moskowitz, C.H., Bertino, J.R., Glassman, J.R., Hedrick, E.E., Hunte, S., Coady-Lyons, N., Agus, D.B., Goy, A., Jurcic, J., Noy, A., O'Brien, J., Portlock, C.S., Straus, D.S., Childs, B., Frank, R., Yahalom, J., Filippa, D., Louie, D., Nimer, S.D. Zelenetz, A.D. (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology, 17, 3776 3785.
22. Mounier, N., Gisselbrecht, C., Briere, J., Haioun, C., Feugier, P., Offner, F., Recher, C., Stamatoullas, A., Morschhauser, F., Macro, M., Thieblemont, C., Sonet, A., Fabiani, B. Reyes, F. (2004) Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 22, 2826 2834.
23. Pasricha, S.R., Grigg, A., Catalano, J., Leahy, M., Underhill, C., Arthur, C., D'Rozario, J., Lowenthal, R., Reed, K. Spencer, A. (2008) A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. Cancer, 113, 3192 3198.
24. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.Y., Harousseau, J.L., Coiffier, B., Biron, P., Mandelli, F. Chauvin, F. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine, 333, 1540 1545.
25. Ritchie, D., Seymour, J., Grigg, A., Roberts, A., Hoyt, R., Thompson, S., Szer, J. Prince, H. (2007) The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Annals of Hematology, 86, 101 105.
26. Schot, B., van Imhoff, G., Pruim, J., Sluiter, W., Vaalburg, W. Vellenga, E. (2003) Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. British Journal of Haematology, 123, 282 287.
27. Schot, B.W., Pruim, J., van Imhoff, G.W., Sluiter, W.J., Vaalburg, W. Vellenga, E. (2006) The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica, 91, 490 495.
28. Schot, B.W., Zijlstra, J.M., Sluiter, W.J., van Imhoff, G.W., Pruim, J., Vaalburg, W. Vellenga, E. (2007) Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood, 109, 486 491.
29. Shipp, M.A., Abeloff, M.D., Antman, K.H., Carroll, G., Hagenbeek, A., Loeffler, M., Montserrat, E., Radford, J.A., Salles, G., Schmitz, N., Symann, M., Armitage, J.O., Philip, T. Coiffier, B. (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-hodgkin's lymphomas: report of the jury. Journal of Clinical Oncology, 17, 423 429. (Pubitemid 29022421)
30. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Maertens, J., Bormans, G., Thomas, J., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L. Verhoef, G. (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood, 102, 53 59.
31. Stiff, P.J., Dahlberg, S., Forman, S.J., McCall, A.R., Horning, S.J., Nademanee, A.P., Blume, K.G., LeBlanc, M. Fisher, R.I. (1998) Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens - a Southwest Oncology Group trial. Journal of Clinical Oncology, 16, 48 55.
32. Svoboda, J., Andreadis, C., Elstrom, R., Chong, E.A., Downs, L.H., Berkowitz, A., Luger, S.M., Porter, D.L., Nasta, S., Tsai, D., Loren, A.W., Siegel, D.L., Glatstein, E., Alavi, A., Stadtmauer, E.A. Schuster, S.J. (2006) Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 38, 211 216.
33. Velasquez, W.S., Cabanillas, F., Salvador, P., McLaughlin, P., Fridrik, M., Tucker, S., Jagannath, S., Hagemeister, F.B., Redman, J.R., Swan, F. Barlogie, B. (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood, 71, 117 122.
34. Velasquez, W.S., McLaughlin, P., Tucker, S., Hagemeister, F.B., Swan, F., Rodriguez, M.A., Romaguera, J., Rubenstein, E. Cabanillas, F. (1994) ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. Journal of Clinical Oncology, 12, 1169 1176.
35. Vose, J.M., Zhang, M.J., Rowlings, P.A., Lazarus, H.M., Bolwell, B.J., Freytes, C.O., Pavlovsky, S., Keating, A., Yanes, B., van Besien, K., Armitage, J.O. Horowitz, M.M. and others of the Autologous Blood and Marrow Transplant Registry Lymphoma Working Committee 2001) Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. Journal of Clinical Oncology, 19, 406 413.